Market Place
Sourcing Support
Actinium Pharma Highlights Antibody Radiation Conjugate Progress
18 Nov 2024 //
PR NEWSWIRE
Actinium Appoints Dr. June Almenoff to Board of Directors
04 Nov 2024 //
PR NEWSWIRE
Actinium Publishes Results from the Phase 3 SIERRA Trial of Iomab-
20 Sep 2024 //
PR NEWSWIRE
FDA Rejects Actinium`s Blood Cancer Therapy Filing Plans
05 Aug 2024 //
FIERCE BIOTECH
Actinium Updates On Iomab-B BLA Filing And Future US Plans
05 Aug 2024 //
PR NEWSWIRE
Actinium Expands Patent Coverage For Iomab-ACT
01 Aug 2024 //
PR NEWSWIRE
Actinium To Present At Targeted Radiopharmaceuticals Summit US
25 Jul 2024 //
PR NEWSWIRE
ITF Therapeutics Launches DUVYZAT For Duchenne Muscular Dystrophy
25 Jul 2024 //
PR NEWSWIRE
Actinium Presents Actimab-A Data At 2024 EHA Congress
17 Jun 2024 //
PR NEWSWIRE
Actinium Highlights Iomab-B Data In TP53 Positive AML At EHA
14 Jun 2024 //
PR NEWSWIRE
Actinium`s Actimab-A + CLAG-M Data At SNMMI 2024 Meeting
11 Jun 2024 //
PR NEWSWIRE
Actinium Highlights Iomab-B Mutation Data, Linker Tech At SNMMI 2024
10 Jun 2024 //
PR NEWSWIRE
Actinium To Host KOL Webinar On Iomab-ACT CAR-T Trial Design
15 May 2024 //
PR NEWSWIRE
Actinium Presents TP53+ Survival, Iomab-B Long-Term Data At EHA 2024
14 May 2024 //
PR NEWSWIRE
Actinium Highlights Radiation Conjugates At SNMMI 2024 Annual Meeting
13 May 2024 //
PR NEWSWIRE
Actinium Webinar On Iomab-ACT CAR-T Trial At UT Southwestern
07 May 2024 //
PR NEWSWIRE
Actinium: Iomab-B Overcomes TP53 Mutation In R/R AML
18 Apr 2024 //
PR NEWSWIRE
Actinium Announces Ph 3 Trial Results Demonstrating Survival Benefit in AML
01 Apr 2024 //
PR NEWSWIRE
Actinium Announces Trial to Study with Leading FDA-Approved CAR T-Cell Therapy
26 Mar 2024 //
PR NEWSWIRE
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative
11 Mar 2024 //
PR NEWSWIRE
Actinium Announces Iomab-B Markedly Increases Long Term Survival in AML
26 Feb 2024 //
PR NEWSWIRE
Actinium Highlights Improved Survival with Iomab-B in Leukemia Patients
23 Feb 2024 //
PR NEWSWIRE
Actinium Announces Acceptance of Five Abstracts for Presentation
02 Jan 2024 //
PR NEWSWIRE
Actinium`s Presentations at ASH Highlight Outcomes for Iomab-B and Actimab-A
11 Dec 2023 //
PR NEWSWIRE
Actinium Announces Iomab-B Produces High Response Rates in AML Patients
11 Dec 2023 //
PR NEWSWIRE
Actinium to Highlight Potential of Targeted Radiotherapies Iomab-B and Actimab-A
08 Dec 2023 //
PR NEWSWIRE
Actinium Presents Data Showing Actimab-A`s Potential to Restore T Cell Immunity
06 Nov 2023 //
PR NEWSWIRE
Actinium Appoints Lynn Bodarky as Chief Business Officer
03 Nov 2023 //
PR NEWSWIRE
Actinium Announces Oral Presentation at ASH Annual Meeting
02 Nov 2023 //
PR NEWSWIRE
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
02 Nov 2023 //
PR NEWSWIRE
Actinium Announces NIH Grant Extension to Advance Development of CD45
04 Oct 2023 //
PR NEWSWIRE
Actinium Pharma Highlights Abstract Accepted for Poster Presentation
27 Sep 2023 //
PR NEWSWIRE
Actinium Pharma to Present at 2nd Annual Targeted Radiopharmaceuticals Summit
24 Jul 2023 //
PR NEWSWIRE
SNMMI Annual Meeting Abstract of the Year Awarded to Actinium`s Iomab-B Phase 3
26 Jun 2023 //
PR NEWSWIRE
Actinium Highlights Six Abstracts Accepted for Oral and Poster Presentation
23 Jun 2023 //
PR NEWSWIRE
Actinium Pharma to Present at the Maxim Healthcare Virtual Conference
16 Jun 2023 //
PR NEWSWIRE
Actinium Announces Phase 3 SIERRA Trial Results in Presentation at the EHA
12 Jun 2023 //
PR NEWSWIRE
Actinium Announces Abstracts Accepted for Presentation at the SNMMI
22 May 2023 //
PR NEWSWIRE
Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals
10 May 2023 //
PR NEWSWIRE
Actinium Highlights Successful Administration of Targeted Radiotherapy Iomab-B
28 Apr 2023 //
PR NEWSWIRE
Actinium Announces +ve Pivotal Ph3 SIERRA Trial Results of Iomab-B Showcased
27 Apr 2023 //
PR NEWSWIRE
Actinium Presents Data Demonstrating Actimab-A`s Use Against Solid Tumors
19 Apr 2023 //
PR NEWSWIRE
Actinium Highlights 1st-In-Class HER3 Targeted Radiotherapy Data Demonstrating
19 Apr 2023 //
PR NEWSWIRE
Actinium to Showcase Targeted Radiotherapies in Two Presentations
16 Mar 2023 //
PR NEWSWIRE
Actinium to Present at Oppenheimer`s 33rd Annual Healthcare Conference
15 Mar 2023 //
PR NEWSWIRE
Actinium details PhIII win for radiotherapy in acute myeloid leukemia
21 Feb 2023 //
ENDPTS
Actinium Announces Data Results From the Pivotal Phase 3 SIERRA Trial
18 Feb 2023 //
PR NEWSWIRE
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial
14 Feb 2023 //
PR NEWSWIRE
Actinium, NCI Partner to Develop Actimab-A in AML
06 Feb 2023 //
CONTRACT PHARMA
Actinium Signs Cooperative R&D Agreement with National Cancer Institute
06 Feb 2023 //
PR NEWSWIRE
Actinium to Present at the 3rd Annual B. Riley Securities Oncology Conference
17 Jan 2023 //
PR NEWSWIRE
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Presentation
12 Jan 2023 //
PR NEWSWIRE
Actinium Highlights Survival Data in AML Patients with Venetoclax Treatment
12 Dec 2022 //
PRNEWSWIRE
Actinium Announces Collaboration with Columbia University to Study Actimab-A
08 Dec 2022 //
PRNEWSWIRE
Actinium sheds 15% after shareholder letter
22 Nov 2022 //
SEEKING ALPHA
Actinium Announces 1-Year and 2-Year Survival Data for Patients with Relapsed
03 Nov 2022 //
PRNEWSWIRE
Actinium Appoints Seasoned Leader Caroline Yarbrough asChief Commercial Officer
02 Nov 2022 //
PRESS RELEASE
After years of effort, Actinium meets primary endpoint in pivotal AML trial
31 Oct 2022 //
ENDPTS
Actinium Expands Clinical Leadership Team to Support Iomab-B and Actimab-A
27 Oct 2022 //
PRESS RELEASE
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
26 Oct 2022 //
PRNEWSWIRE
